What are the payment terms accepted?

Accepted payment methods include LC, T/T, D/P, PayPal, Western Union, and small-amount payments.

Poultry Vaccine Infectious Bronchitis Vaccine, Live (Strain H52) GMP Factory

Name: Poultry Vaccine Infectious Bronchitis Vaccine, Live (Strain H52) GMP Factory
Brand: Henan Muxiang Biological Co., Ltd.
SKU: 1937289782

Henan, ChinaHenan Muxiang Biological Co., Ltd.

Negotiable

1,000 Pieces

Sample price:US$12.00/piece.Request sample

Product profile

Customization

Available

Varieties

General Disease Prevention Medicine

Component

Animal

Model NO.

1000feathers/bottle

Type

The First Class

Pharmacodynamic Influential Factors

Combined Medication

Storage Method

Prevent High or LowTemperature

Transport Package

Carton

Specification

1000feathers/bottle

Trademark

MOOSUN; QIXIANG

Origin

China

Production Capacity

50000pieces/Month

Key features

Effective Immunity Period: Provides immunity for 6 months, developing 5-8 days after vaccination.

Flexible Dosage Methods: Can be administered via nasal dropping or drinking water for chickens over 1 month old.

Multiple Package Sizes: Available in 100, 250, 500, 1000, and 2000 feathers per bottle with various carton options.

GMP Factory Production: Manufactured in a certified GMP facility ensuring high quality standards.

OEM and ODM Services: Custom branding and manufacturing services available for clients.

Rapid Response Time: Average lead time is one month for both peak and off-peak seasons.

Global Market Reach: Exports to North America, Europe, Asia, Africa, and Australia.

Company profile

Henan Muxiang Biological Co., Ltd.

Henan, China

CertifiedBusiness Type: Manufacturer/Factory & Trading Company CertifiedR&D Capacity: ODM Service Available & OEM Service AvailableExport Year: 2016-02-01 CertifiedNearest Port: Shanghai Port, Qingdao PortAverage Response Time: ≤15h CertifiedTerms of Payment: LC, T/T, D/P, etc.

AI-Powered supplier vetting

SummaryHenan Muxiang Biological Co., Ltd. is a China-based limited-company factory established in 2004, with 360 employees and operations in veterinary pharmaceuticals and animal-health products. The supplier reports seven pharmaceutical production lines, eight vaccine production lines, first-class production and inspection equipment, GMP management, ISO9001:2015 certification, and ISO/CNAS laboratory certification. Its R&D resources include more than 40 core personnel, over 30 of whom hold doctoral or master's degrees, while 21–30 quality-control staff are reported. The company exports to multiple global regions, has self-operated import and export rights, and states a one-month order-fulfillment period in both peak and off-peak seasons. Evidence supports capabilities in certification, innovation, production, and international operations. However, the provided information does not sufficiently establish after-sales service performance, financial credibility, customization execution, or specific customer cases.

Supplier typeThe supplier is identified as a limited company and a factory in the manufacturing industry, with its operating location in Henan, China. This indicates a direct manufacturing entity rather than only a trading or intermediary business.

CertificationsThe supplier reports a systematic GMP management system, ISO/CNAS laboratory international certification, and an ISO9001:2015 certificate. These stated certifications and quality systems provide explicit evidence of formal quality-management capability.

R&D capabilityThe supplier reports more than 40 core R&D personnel, including over 30 doctors or master's degree graduates, 20 years of preparation-technology experience among R&D engineers, and advanced R&D platforms such as a National Enterprise Technology Center, National Postdoctoral Research Station, and Academician Workstation. It also reports improving herbal active-ingredient extraction by more than 30% versus a traditional process, supporting a strong stated innovation profile.

Production capacityThe supplier reports seven pharmaceutical production lines and eight vaccine production lines, first-class production and inspection equipment, six production lines in a separate operational data field, and one-month order fulfillment in both peak and off-peak seasons. Although the line-count figures are not fully consistent across the slices, the evidence clearly supports substantial pharmaceutical and vaccine manufacturing capability.